Michael Ulz
Stock Analyst at Morgan Stanley
(4.69)
# 132
Out of 5,172 analysts
105
Total ratings
61.67%
Success rate
37.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Overweight | $50 → $47 | $17.56 | +167.65% | 4 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Equal-Weight | $29 → $7 | $4.07 | +71.99% | 2 | Mar 2, 2026 | |
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.44 | +353.21% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $88.51 | +38.97% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $312.17 | +30.70% | 13 | Jan 30, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $48 → $81 | $56.33 | +43.80% | 7 | Jan 7, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $7.94 | +214.86% | 3 | Dec 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $70.99 | +32.41% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $32.33 | +215.50% | 4 | Oct 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $7.63 | +175.23% | 8 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $25 | $6.17 | +305.19% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $2.94 | +648.30% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $3.69 | +442.01% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.10 | +536.36% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $11.16 | +141.94% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.92 | +2,073.91% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $4.14 | +986.96% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $140 | $7.86 | +1,681.17% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.40 | -31.82% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $9.10 | +229.67% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $19.87 | +302.62% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.43 | +3.95% | 3 | Jul 12, 2017 |
Dyne Therapeutics
Mar 3, 2026
Maintains: Overweight
Price Target: $50 → $47
Current: $17.56
Upside: +167.65%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Equal-Weight
Price Target: $29 → $7
Current: $4.07
Upside: +71.99%
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.44
Upside: +353.21%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $88.51
Upside: +38.97%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $312.17
Upside: +30.70%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Equal-Weight
Price Target: $48 → $81
Current: $56.33
Upside: +43.80%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $7.94
Upside: +214.86%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $70.99
Upside: +32.41%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $32.33
Upside: +215.50%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $7.63
Upside: +175.23%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.17
Upside: +305.19%
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.94
Upside: +648.30%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.69
Upside: +442.01%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.10
Upside: +536.36%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $11.16
Upside: +141.94%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.92
Upside: +2,073.91%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $4.14
Upside: +986.96%
Jan 27, 2023
Maintains: Overweight
Price Target: $280 → $140
Current: $7.86
Upside: +1,681.17%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.40
Upside: -31.82%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $9.10
Upside: +229.67%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $19.87
Upside: +302.62%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.43
Upside: +3.95%